CR1 and breast carcinoma: Consistent with the notion that there was a difference in trans-acting factor(s) binding to CR1, mutations of TFBSs for AP-1and NFκB resulted in a significant reduction in GFP expression in two breast cancer cell lines (Fig. 4).